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Abstract The aim of this study was to propose and validate
a new unified method for testing dissolution rates of bioac-
tive glasses and their variants, and the formation of calcium
phosphate layer formation on their surface, which is an indi-
cator of bioactivity. At present, comparison in the literature
is difficult as many groups use different testing protocols.
An ISO standard covers the use of simulated body fluid on
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standard shape materials but it does not take into account
that bioactive glasses can have very different specific surface
areas, as for glass powders. Validation of the proposed mod-
ified test was through round robin testing and comparison
to the ISO standard where appropriate. The proposed test
uses fixed mass per solution volume ratio and agitated solu-
tion. The round robin study showed differences in hydrox-
yapatite nucleation on glasses of different composition and
between glasses of the same composition but different par-
ticle size. The results were reproducible between research
facilities. Researchers should use this method when testing
new glasses, or their variants, to enable comparison between
the literature in the future.
Keywords Bioactivity test · SBF · Hydroxycarbonated
apatite · Bioglass · NovaBone · BonAlive · 13-93 ·
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1 Introduction
Bioactive glasses have huge potential as materials for bone
regeneration. The original bioactive glass, developed by Lar-
ry Hench, had the 45S5 composition (46.1 mol% SiO2, 26.9
mol% CaO, 24.4 mol% Na2O, 2.6 mol% P2O5) and was
termed Bioglass R©[1]. In vivo studies showed it to bond to
bone and stimulate more bone growth than particles of syn-
thetic hydroxyapatite and apatite-wollastonite glass-ceramics
[2]. The mechanism of bone bonding is through the forma-
tion of a surface layer of hydroxycarbonate apatite (HCA),
which is similar to the mineral component of bone [3]. The
HCA layer forms following cation exchange from the glass
with protons from body fluid, which leaves a poorly con-
nected silica rich layer [4]. Calcium phosphate precipitates
on the silica rich layer and crystallises to form HCA [1]. The
Bioglass composition is commercially available, in particu-
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late form, as a synthetic bone graft NovaBoneT M (NovaBone
Products LLC, Jacksonville FL) and has been implanted in
more than 1 million patients. A finer particulate form of the
same glass is now also used to treat dental hypersensitiv-
ity by incorporation into toothpaste [5]. Since its develop-
ment, there has been a lot of work investigating the effect
of glass composition; morphology (particle versus mono-
lith versus fibre versus scaffold) and glass type (melt versus
sol-gel) on rate of dissolution and apatite formation in vitro.
However many of the research articles describing the work
present different protocols for testing the glass dissolution
and apatite forming ability, making it difficult for the reader
to make comparisons.
For this reason, an ISO standard has been proposed for
the testing of the apatite forming ability of medical implants
(ISO / FDIS 23317/, Implants for surgery In vitro evalu-
ation for apatite-forming ability of implant materials) [6].
However this test was designed for testing bioceramic or
glass-ceramic coatings on metal substrates or for monolithic
(disc) shaped samples. It does not translate well to powder
or porous bioactive glasses. There are two main reasons for
this: i) the ISO test fixes the surface area to solution volume
ratio when comparing samples; ii) the test is static. Keep-
ing surface area constant allows comparison between sam-
ples of different compositions but does not allow compari-
son between samples of the same composition but different
morphologies. Surgeons are likely to use such materials for
filling a bone defect of a certain volume, so fixing surface
area would not be suitable for the development of bioactive
glass fibres and porous scaffolds [7, 8, 9, 10]. Sol-gel glasses
also have specific surface areas several orders of magnitude
higher than melt-derived glasses, for the same particle size,
due to their inherent nanoporosity. Therefore fixing surface
area to compare dissolution of a sol-gel and a melt-derived
glass would not even be possible, and would not be a valid
test.
The aim is not to develop a method for predicting whether
materials will form a bond with bone. As reported previ-
ously, in vitro conditions cannot match those in vivo, and
a simulated body fluid does not exist that exactly matches
those of the human body [11]. Instead, the aim is to develop
a facile test that can be used in most research laboratories
around the world and allow comparison of dissolution rates
and apatite nucleation. The test is a modification of the ISO
standard, which uses simulated body fluid [12]. The pro-
posed test agreed upon by Technical Committee 4 (TC04)
of the International Commission on Glass (ICG) and will be
referred to here as the TC04 method. This test was validated
through a round robin study in eight different laboratories
in seven countries to ensure reproducibility and to compare
to the ISO standard. High purity, commercial glasses were
used that were produced under Good Manufacturing Prac-
tice (GMP), 5 melt and 1 sol-gel derived. NovaBone (NB) is
the commercial form of Bioglass, which has a broad parti-
cle size distribution. BonAliveT M (BA, Vivoxid, Turku, Fin-
land) is another melt-derived particulate with a different ra-
tio of its component oxides [13]. 13-93 is a composition that
was originally was designed for fibre drawing, as it is dif-
ficult to pull Bioglass fibres without the glass crystallising
[14]. More recently it has been used to produce scaffolds for
bone regneration [7]. StonBone has a similar composition to
Bioglass, except that some of the calcium was substituted
with strontium [15]. TheraGlass (TheraGlass Ltd., London,
UK) is a binary sol-gel derived glass [16]. Details of the
glass compositions are given in Table 1.
2 Materials and Methods
2.1 The bioactive glasses
Commercial samples of bioactive glasses were used to en-
sure all groups had reproducible samples. All the different
elemental compositions are details in Table 1. BonAlive (Viv-
oxid, Turku, Finland) has a particle size range of 45-90µm
(BA). Mo-Sci (Rolla, MO) kindly produced 45S5 Bioglass
(BG) and 13-93 to the same particle size range. Sr-Bioglass
(Sr-BG) of the same particle size range was provided by
RepRegen Ltd. (London, UK). A sol-gel derived bioactive
glass TheraGlass (TG) was provided by MedCell Bioscience.
The particle sizing was carried out by sieving. Bioglass 45S5
is marketed as NovaBone (NB) with a specified particle size
range of 90-710µm provided by Novabone LLC (Jacksonville,
FL).
Table 1 Elemental composition of the bioactive glasses tested given in
mol%.†Novabone and 45S5 Bioglass have the same elemental compo-
sition but different particle sizes
Glass SiO2 CaO Na2O P2O5 SrO K2O MgO
45S5† 46.1 26.9 24.4 2.6 - - -
13-93 54.6 22.1 6.0 1.7 - 7.9 7.7
BA 53.8 21.9 22.7 1.7 - - -
Sr-BG 44.5 21.5 27.2 4.4 2.4 - -
TG 70.0 30.0 - - - - -
2.2 Pre-test characterization
Surface area and density measurement : Nitrogen sorption
was used to estimate the surface area of the glass powders
(Autosorb AS6, QuantaChrome). In order to remove any
trace of moisture, samples were degassed at 150◦C for 8h
before analysis (Degasser, Quantachrome). Specific surface
areas were calculated by fitting the first seven points (rela-
tive pressures of 0.05-0.3) of the adsorption branch of the
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isotherm to the BET equation [17]. Skeletal density was
determined by helium pycnometry (Ultrapycnometer 1000,
QuantaChrome) on glasses, with the use of a known mass of
powder previously dried at 80◦C for 24 h.
Particle size analysis: Particle sizes were measured using a
laser diffraction (Malvern Mastersizer 2000 equipped with a
Hydro 2000 SM dispersion unit). The volume average par-
ticle diameters D quoted are obtained from at least 5 repeat
runs. d(0,5) is the diameter under which 50% of the particles
fall.
2.3 Bioactivity tests
Simulated body fluid preparation: Simulated body fluid (S
BF) was prepared according to Kokubo’s method [12]. Rea-
gents (Table 2) were provided by Sigma-Aldrich UK and
used as received without further purification. To produce 1
L of SBF, 700 mL of deionized (DI) water was placed in a
1 L polypropylene beaker and set at 37◦C± 1.0◦C in a wa-
ter bath. The solution was continuously stirred throughout.
The reagents were slowly added to the DI water in the order
given in Table 2 with an accuracy of ±0.5 mg. The pH was
monitored to avoid any rapid increase, which would cause
precipitation. Once the reagents were mixed, the SBF was
transferred to a 1 L volumetric flask and filled to the mark
with DI water once cooled at RT. SBF was stored at 37◦C
and used within 2 days. The pH was adjusted to 7.4 before
use at 37◦C.
Table 2 Reagents used for preparing SBF solution
Order Reagent Amount (g.L−1) CAS number
1 NaCl 8.035 7647-14-5
2 NaHCO3 0.355 144-55-8
3 KCl 0.225 7447-40-7
4 K2HPO4·3H2O 0.231 16788-57-1
5 MgCL2·6H2O 0.311 7791-18-6
6 HCL 1M 38 mL 7647-01-0
7 CaCl2·2H2O 0.386 10035-04-8
8 NaSO4 0.072 7757-82-6
9 Tris 6.118 77-86-1
TC04 method: Bioactivity of powders based on concentra-
tion: Bioactive glass powders were immersed in SBF using
a ratio of 75 mg glass to 50 mL SBF in an airtight polyethy-
lene container. Dissolution vessels were placed in an incu-
bating orbital shaker held at 37◦C, agitated at 120 rpm. The
pH and temperature of the media was verified before use.
The samples were incubated for 7 different time points: 4 h,
8 h, 24 h, 72 h, 1 week, 2 weeks, 3 weeks and 4 weeks. At the
end of each time period, the sample was removed from the
incubator and the solids were collected by filtration (particle
retention 513 µm). The powder was immediately washed
with DI and subsequently with acetone to terminate any re-
action. Each sample was run in triplicate. The filtered solu-
tion was collected to determine the ion concentrations using
an induced coupled plasma (ICP) analysis; the pH of the so-
lution was also measured. The same protocol was applied to
SBF alone as a control.
ISO / FDIS 23317: Bioactivity of powders based on surface
area: Bioactive glass powders were immersed in SBF us-
ing a fixed volume to surface area ratio: VSBF =100*Sa,glass
where VSBF is the volume of SBF used and Sa,glass the ap-
parent surface area of the specimen. Here, the mass of glass
particles used for each composition was calculated for 100
mL of SBF. The rest of the protocol was the same as previ-
ous test except that samples were not agitated. Each sample
was run in triplicate. This ISO standard was designed for
solid disc shaped samples, so discs of 13-93 composition
were also tested.
2.4 Post-test characterization
Inductive coupled plasma - atomic emission spectroscopy:
Concentrations in solution were measured with a Thermo
Scientific iCAP 6300 Duo inductive coupled plasma - op-
tical emission spectrometer (ICP-AES) with auto sampler.
Sample solutions were prepared by diluting the samples by
a factor of 10 with analytical grade 2 M HNO3. Mixed stan-
dards of silicon, phosphorous, calcium, sodium and potas-
sium were prepared at 0, 2, 5, 20 and 40 µg.mL−1 for the
calibration curve. Silicon and phosphorous were measured
in the axial direction of the plasma flame whereas calcium,
sodium and potassium were measured in the radial direction.
Fourier transform infrared spectroscopy: KBr pellets con-
taining bioactive glass powder were prepared under 8 tons
of pressure at a ratio of 2 wt% of sample to KBr. Fourier
transform infrared spectroscopy (FTIR) was performed us-
ing a Thermo Nicolet Nexus 670 FTIR purged with nitrogen
in transmission mode with a spectral resolution of 2 cm−1
from 4000 to 400 cm−1. Spectra were collected as mean of
32 scans and plotted as adsorption.
X-Ray diffraction : X-ray diffraction (XRD) patterns of glas-
ses before and after immersion in SBF were recorded using
a Panalytical Xpert Pro MPD. The radiation source was a Ni
filtered Cuκα . Diffraction was measured continuously from
6 to 70◦ 2θ , with a step size of 0.026◦ and a time per step of
100 seconds.
4 Anthony L. B. Mac¸on et al.
Table 3 Size and surface analysis of bioactive glass particles. The estimated surface area was calculated using Estimated SSA = 3ρs∗r , where r is
particle radius and ρs the skeletal density. The last column represents the mass of glass used for the ISO standard.
Glass Sample Network Particle size ρs, Density Estimated SSA BET SSA Mass required
code connectivity (NC) d50, (µm) D, (µm) (g.cm−3) (m2.g−1) (m2.g−1) (mg/100mL)
Bioglass BG 2.1 74.4±1.0 76.1±1.2 2.71 0.029 0.24 4.17
NovaBone NB 2.1 22.5±2.1 87.6±7.2 2.72 0.025 0.36 2.78
13-93 13-93 2.6 76.5±1.4 79.9±1.45 2.76 0.027 0.09 11.11
BonAlive BA 2.5 73.4±0.3 77.5±0.4 2.66 0.028 0.21 4.76
Sr-Bioglass Sr-BG 2.3 76.8±0.4 81.1±0.6 2.81 0.027 0.20 5.0
Theraglass TG - 42.9±0.2 45.5±0.1 2.71 0.047 78.02 0.012
Scanning electron microscopy : Field emission gun scan-
ning electron microscopy (FEG-SEM) was performed on a
JEOL 7100 using a gun voltage of 15 kV and a working
distance of 10 mm. Samples were mounted on double sided
carbon tape and coated with gold.
Statistics: Where required, sample sets were statistically tes-
ted against a null hypothesis using a t-test implemented on
Matlab R2013b (function t-test2). Samples were considered
pai-red with equal size and unequal variance. The level of
statistical significance was fixed at 0.05.
3 Results and Discussion
3.1 Pre-test characterisation
Each company sized their particles by sieving, using sieves
of 90 µm and 45 µm, with the exception of NovaBone, who
used sieves of 90 µm and 710 µm. As dissolution is depen-
dent on surface area, it was important to measure the actual
particle size distributions (refer to supplementary figure)[18].
Table 3 shows the d50 which is the diameter under which
50% of the particles fall and D which is an arithmetic vol-
ume average of the particle equivalent diameters. The d50
and D values were similar (within 5 µm) for all powders,
except NovaBone. This means that all glasses except Nov-
aBone had Gaussian-like particle size distributions. Nov-
aBone had a trimodal distribution with modes at 0.4 µm,
11.5 µm and 208.9 µm. All melt-derived powders with the
specified ranges of 45-90 µm also had similar values d50
and D values (73-87 µm). TheraGlass particles were smaller
(D of 45.5 µm), which is likely to be due to their inherent
nanoporosity, making grinding easier.
The skeletal density, ρs, of all the glasses where similar
at approximately 2.7 gcm−3 (see Table 3).
Limitation of ISO / FDIS 23317 for bioactive glasses: This
method was designed only for solid, regular geometric shaped
samples, such as dics or tiles and was never designed for
glass powders or porous materials. This leads to the first
problem with carrying out the bioactivity testing with the
ISO standard; the measurement of the surface area of the
glass powders. Consistent measurement of specific surface
area (SSA) for glass particles exceeding 30 µm in size is
difficult. Two methods were used: i) combination of the par-
ticle size distribution and the density of the particles; ii) gas
adsorption using the BET method [19]. The first method in-
correctly assumes that all particles were spherical, under-
estimating the surface area due to the angularity of ground
glass powders (Table 3). It also did not take into account the
intrinsic nanoporosity of the sol-gel derived glass (TG). Ni-
trogen sorption did take the porosity into account and the
data for TG were in good agreement with the literature [20].
However, the BET SSA values for the melt derived glasses
were small, ranging from 0.20 to 0.36 m2.g−1, which are be-
low the accurate detection limits of 1 m2.g−1 [21, 22]. Once
SSA was obtained, the quantity of glass needed to perform
the ISO standard in 100 mL of SBF was calculated using
BET SSA (Table 3). Values for the melt-derived glasses var-
ied from 2.78 to 5 mg for 100 mL of SBF. However, for the
sol-gel derived glass the amount of glass was impractical
(0.012 mg per 100 mL of SBF). Therefore, only the melt-
derived glasses were tested with the ISO standard.
3.2 Bioactivity of commercially available bioactive glasses.
The TC04 method fixes the mass of glass in SBF was com-
pared to the ISO test, which used a consistent surface area.
For both tests, the concentration of silicon, calcium and
phosphorus and the pH value varied over the length of the
test compared with SBF alone (Figure 1). The rise in pH was
due to the cation exchange, predominantly of Na+ and Ca2+
from the glasses with protons from the solution [4]. Using
the TC04 method, the pH level after 4 weeks increased with
the amount of cations present originally in the glass com-
position. There was no such pattern observed with the ISO
standard. This is due to the low mass of melt-derived glass
powder in the ISO standard test, releasing such a low con-
centration of cations that it did not disturb the buffering ca-
pacity of SBF. To test this hypothesis, a disc of 13-93 glass
was tested by the ISO test. The SSA of the disc was 0.00465
m2.g−1, so the 0.082 g was immersed in 64 mL of SBF.
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Fig. 1 Dissolution profiles as a function of time for bioactive glasses using a) the TC04 method and b) the ISO standard (Could not be used for
the sol-gel glass TG).
This led to a pH of 7.71 at 4 weeks, with [Ca] of 97.0±2.7
µg.mL−1, due the higher mass of glass. The silica (57.6±1.4
µg.mL−1) and calcium release from the disc were similar
to that of the powders in the TC04 method. The difference
was the phosphorous depletion in the SBF was slower for
the disc in the ISO standard compared to the powder in the
TC04 method, as the surface area of the powder was greater,
which is likely to enhance HCA formation.
In the TC04 test, the pH rise for TG was in the same
order as that for NB after 4 weeks of dissolution (pH=8.05
and 8.09 respectively, p>0.5). However, TG only contains
30 mol% of CaO (compared to 26.9 mol% for NB), which
indicated that the intrinsic nanoporosity enhanced its disso-
lution [23, 24]. In addition sol-gel glasses have lower net-
work connectivity (number of bridging oxygen bonds per
silicon atom) than their nominal composition suggests, due
to the presence of Si-OH groups, where H+ ions act as ad-
ditional network modifiers [20].
The soluble silica release profiles for all compositions
showed an increase in the concentration, following a neg-
ative exponential trend, levelling off after 3 days of disso-
lution. However, the [Si] profiles differed between the two
tests. In the TC04 test, the soluble silica released at different
rates depending on glass compositions (see Supplementary
Table 1), but the final concentration after 4 weeks was stati-
cally equivalent among all glasses ([Si]4wks=60.2 µg.mL−1,
p>0.25). However, the amount of soluble silica released us-
ing the ISO standard was directly proportional to the initial
mass of glass (Supplementary Figure II). This would falsely
imply that 13-93 degraded faster than NB as both glasses
had theoretically the same surface exposed to the media.
However, there was a greater mass of 13-93 initially im-
mersed in the SBF (11.11 mg) than NB (2.78 mg), due to
the difference in the measured surface area between 13-93
and NB. Due to the inaccuracy of the BET method for these
particles, more 13-93 glass was immersed in the SBF, caus-
ing the absolute amount of silica release to be higher. 13-93
is known to have a higher network connectivity than 45S5
making the glass more resistant to degradation (Table 3)[25].
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The concentration of calcium and phosphorus in SBF
were also monitored as a function of time. A decrease in
their level is usually considered as a good indicator of bioac-
tivity [18]. SBF contains approximately 90 µg.mL−1 of cal-
cium ions and 30 µg.mL−1 of phosphorus. The release of
calcium followed the trend of the silica release over the first
day of dissolution when using the TC04 method, showing
a homogeneous degradation of the glass. Subsequently, for
glasses with the lower amounts of calcium in their com-
position (13-93 and BA) calcium concentration in SBF de-
creased, whereas all the other compositions levelled off. For
instance, despite having released the same amount of cal-
cium within 24h (155 µg.mL−1, p>0.15), [Ca] for BA (20
mol% CaO) dropped to 123±7.6 µg.mL−1 at 4 weeks wher-
eas [Ca] for BG (26.9mol% CaO) increased to 209.3±24.4
µg.mL−1. The concentration of phosphorus decreased for
all compositions regardless of the method used. However,
the TC04 method exhibited a more defined and more rapid
decrease in [P]. As an example, 13-93 had an immediate de-
crease in [P] approaching 0.5 µg.mL−1 at 1 week, using the
TC04 method, whereas [P] started to decline only after 2
weeks using the ISO standard method. Again, this could be
due to a lower mass of glass present in the ISO standard, but
could also be due to the agitation in the TC04 test [26].
3.3 Post-test surface characterisation
Apatite nucleates on the surface of the different bioactive
glasses, all the participants of this round robin test were
asked to investigate surface chemistry changes using FTIR
and XRD. Due to the small mass of glass powder used in
the proposed standard, only FTIR analysis was carried out
on these solids, which are given in supplementary infor-
mation (Figure SIII). Figure 2 shows the FTIR spectra ob-
tained after 4 weeks immersion in SBF (TC04 method). The
mechanism of apatite formation is known to involve silica-
rich layer formation at the glass surface, following cation
exchange, containing Si-OH groups that act as nucleation
sites for amorphous calcium-phosphate[27, 28]. The local
pH increase promotes calcium-phosphate (Ca-P) crystalli-
sation where the tetrahedral PO−34 exhibits sharp IR absorp-
tions at 565 and 605 cm−1, characteristic of P-O bending,
and at 1030 cm−1, characteristic of P-O stretching[29, 30].
Spectra collected from BG showed the P-O bending vibra-
tion bands after 24 h of immersion in SBF (Figure 2-a).
Other bands characteristic of carbonate group, CO−23 , were
detected at 1460 cm−1, 1420 cm−1 and 875 cm−1, which is a
sign of B-type carbonated apatite precipitation : Ca9(HPO4)0.5
(CO3)0.5(PO4)5OH (HCA), mimicking bone like apatite[3,
31]. The precipitation of pure hydroxyapatite (HA) is less
likely to happen in SBF as it is saturated with respect of
slightly carbonated apatite, where the orthophosphates are
substituted by carbonates in the crystal lattice[32]. Only TG
was found to nucleate Ca-P crystal at a similar (fast) rate to
BG. Sol-gel derived glasses, due to their higher surface area,
the abundance of OH groups and low network connectivity
are better inducer of nucleation than melt derived glasses
of similar compositions[23, 28]. All the other glasses were
found to nucleate apatite slower (Figure 2-b). Time points
at which apatite did nucleate on the glasses is discussed the
results of the round robin study section below. Something to
consider with FTIR spectra is that the P-O bending bands are
not characteristic to HA or HCA, they indicate the presence
of orthophosphate lattices [33].
Therefore, to confirm the nature of the newly crystalline
phase formed at the surface the different glasses, X-ray dif-
fraction was carried out as shown in Figure 3. XRD results
were in good agreement with FTIR with crystalline peaks
observed at 24 h for BG, confirming abundant HCA forma-
tion on the surface of the glass, with sharp peak at 2θ ≈
26◦ and 32◦ and a positive correlation of the other peaks
with external reference (ICSD 01-084-1998). The bioactiv-
ity of BG reported here was in agreement with literature[18].
However, a mixture of HCA and calcite (calcium carbonate,
ICSD 52151) was found on the surface of TheraGlass, high-
lighting the importance and the complementarity of XRD
with FTIR. This observation had already been made by Mar-
tinez et. al. who investigated the bioactivity of CaO-SiO2 bi-
nary sol-gel glasses[34]. For their bioactivity test, disks were
produce of the dimension recommended by the ISO method,
overlooking the higher surface area of the sol-gel glass[12].
Interestingly, crystalline phases were sharper and more de-
fined using the TC04 proposed here, due to the increase in
exposed surface to the media between disk and powder. Fi-
nally, change in morphology due to the dissolution and pre-
cipitation of crystal on the different glasses was analysed by
electron microscopy. The surfaces of the bioactive glasses
were found to be smooth and dense before immersion in
SBF. However, large needle-like structure characteristic to
HA were found to cover almost the entire surface of BG and
TG after 24h of immersion [35]. At the same time point, NB
was found with a mixed of amorphous calcium phosphate
and HCA, corroborating data obtained by XRD and FTIR.
3.4 Round robin outcomes
Figure 5 summarises the results obtained across the 8 institu-
tions that participated in this round robin test. Grey shading
shows HCA was detected by FTIR/XRD, with the fraction
of participants obtaining the same result given in parenthe-
ses. The † symbol indicates where the HCA was appeared
at the same time point in the TC04 and ISO test, i.e. where
the tests agreed according to post test surface analysis. Note
that only 6 out of 8 institutions investigated the bioactivity
of BA. Using the TC04 method, the direct effect of the par-
ticle size on the bioactivity could be seen. BG, which has a
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Fig. 3 XRD spectra of a) Bioglass (BG, 45-90 µm) from 0 to 4 weeks immersion in SBF following the TC04 method and b) for all glass
compositions after 24h immersion in SBF, which was the time point at which HCA was first detected for BG.
smaller particle size range than NB, nucleated more HCA
an earlier time point than NB. The time at which HCA was
found on the surface of the different glasses using FTIR and
XRD was consistent among the participants. BG and TG
were found to be the faster to nucleate HCA, in 24 h, fol-
lowed by Sr-BG, NB and BA, in 72 h. 13-93 was the slow-
est with a nucleation time of 1 week. Nucleation of HCA on
the 13-93 powder occurred 1 week earlier in the TC04 tests
than in the ISO standard. However, the time points were dis-
crete and 1 week apart, as the surface analysis used here
was not continuous. This study therefore also highlights the
importance of using ICP analysis to study dissolution and
apatite formation of bioactive glasses. The change in phos-
phate concentration as a function of time can give a more
accurate information on the precipitation of calcium phos-
phate. The time point where phosphate concentration drops
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Fig. 4 SEM micrographs of bioactive glasses immersed in SBF for 24h by the TC04 method.
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Fig. 5 Histograms representing the time at which HA was revealed by
FTIR and XRD by the 8 different institutions that participated to this
round robin. † indicates the nucleation time using the ISO standard.
Only 6 out of 8 laboratories run BonAlive. Due to its high surface area
(≈80 m2.g−1), TG was not tested using the ISO method
rapidly can be correlated to calcium phosphate precipitation
on the glass surface. ICP can be used to refine the win-
dow of time in which HCA formation occurs. HCA forma-
tion was different for different glass compositions due to the
change in network connectivity (NC) of the glasses[25]. NC
increases with increased silica content (e.g. BA compared
to BG), but also with the introduction of network interme-
diates. 13-93 contains magnesium, of which a proportion is
thought to act as an intermediate, forming -Si-O-Mg-O-Si-
type bonding [36]. The TC04 test is a relatively simple test
that distinguishes between different glasses and should be
employed by groups wanting to test new bioactive glasses,
or their variants, which will enable comparison between the
literature in the future.
4 Conclusion
The aim of this study was to suggest a method for testing
bioactive glasses, particularly those of high surface area, and
to verify the reproducibility of the method by a large number
of research groups working in the field. The protocol was
a modified version of the ISO standard for testing apatite
formation based on sample mass to liquid ratio. Comparison
with the ISO standard showed that the method proposed here
was more appropriate for bioactive glasses, particularly for
particles or glasses with high surface area.
Acknowledgements The International Commission on Glass is thanked
for its support of TC04 and its members. The European Forum of New
Glass Application is also thanked for its support. The authors would
like to thank Vivoxid (Turku, Finland), Mo-Sci (Rolla, MO), RepRegen
Ltd (London, UK) and Novabone LLC (Alachua, FL) for generously
providing samples.
References
1. Hench LL, Splinter RJ, Allen WC, Greenlee TK (1971)
Bonding mechanisms at the interface of ceramic pros-
thetic materials. Journal of Biomedical Materials Re-
search 5:117141
Unified Bioactivity Test 9
2. Oonishi H, Hench LL, Wilson J, Sugihara F, Tsuji E,
Matsuura M, Kin S, Yamamoto T, Mizokawa S (2000)
Quantitative comparison of bone growth behavior in
granules of Bioglass R©, A-W glass-ceramic, and hy-
droxyapatite. Journal of Biomedical Materials Research
51:3746
3. S´los´arczyk A, Paszkiewicza Z, Paluszkiewicz C (2005)
FTIR and XRD evaluation of carbonated hydroxyap-
atite powders synthesized by wet methods. Journal of
Molecular Structure 744-747:657–661
4. Cerruti M, Greenspan D, Powers K (2005) Effect of pH
and ionic strength on the reactivity of Bioglass R© 45S5.
Biomaterials 26:1665–1674
5. Du MQ, Bian Z, Jiang H, Greenspan DC, Burwell
AK, Zhong J, Tai BJ (2008) Clinical evaluation of a
dentifrice containing calcium sodium phosphosilicate
(novamin) for the treatment of dentin hypersensitivity.
American Journal of Dentistry 21:210214
6. Mizuno M (2014) Implants for surgery - In vitro eval-
uation for apatite-forming ability of implant materi-
als. ISO ISO/DIS 23317, International Organization for
Standardization, Geneva, Switzerland
7. Fu Q, Rahaman MN, Bal BS, Brown RF, Day DE
(2008) Mechanical and in vitro performance of 13-93
bioactive glass scaffolds prepared by a polymer foam
replication technique. Acta Biomaterialia 4:1854–1864
8. Quintero F, Pou J, Comensa R, Lusquinos F, Riveiro A,
Mann AB, Hill RG, Wu ZY, Jones JR (2009) Laser spin-
ning of bioactive glass nanofibers. Advanced Functional
Materials 19:3084–3090
9. Brown RF, Day DE, Day TE, Jung S, Rahaman MN,
Fu Q Growth and differentiation of osteoblastic cells on
13-93 bioactive glass fibers and scaffolds
10. Jones JR, Ehrenfried LM, Hench LL (2006) Optimis-
ing bioactive glass scaffolds for bone tissue engineer-
ing. Biomaterials 27:964–973
11. Bohner M, Lemaitre J (2009) Can bioactivity be tested
in vitro with SBF solution? Biomaterials 30:2175–2179
12. kokubo T, Kushitani H, Sakka S, Kitsugi T, Yamamoto
T (1990) Solutions able to reproduce in vivo surface-
structure changes in bioactive glass-ceramic A-W. Jour-
nal of Biomedical Material Research 24:721–734
13. O’Donnell MD (2011) Predicting bioactive glass prop-
erties from the molecular chemical composition: Glass
transition temperature. Acta Biomaterialia 7:2264–
2269
14. Brink M, Turunen T, Happonen RP, Yli-Urpo A (2011)
Compositional dependence of bioactivity of glasses
in the system Na2O-K2O-MgO-CaO-B2O3-P2O5-SiO2.
Acta Biomaterialia 7:2264–2269
15. O’Donnell MD, Candarlioglu PL, Miller CA, Gentle-
man E, Stevens MM (2010) Materials characterisa-
tion and cytotoxic assessment of strontium-substituted
bioactive glasses for bone regeneration. Journal of Ma-
terials Chemistry 20:8934–8941
16. Saravanapavan P, Hench LL (2000) Low-temperature
synthesis, structure, and bioactivity of gel-derived
glasses in the binary CaO-SiO2 system. Journal of
Biomedical Materials Research 54:608–618
17. Brunauer S, Emmett PH, Teller E (1938) Adsorption of
Gasses in Multimolecular Layers. Journal of the Amer-
ican Chemical Society 60:309–319
18. Jones JR, Sepulveda P, Hench LL (2001) Dose-
Dependent Behavior of Bioactive Glass Dissolution.
Journal of Biomedical Materials Research 58:720–726
19. Allen T (1997) Particle Size Measurement: Volume
2: Surface Area and Pore Size Determination. Kluwer
Academic Publishers
20. Lin S, Ionescu C, Pike KJ, Smith ME, Jones JR (2009)
Nanostructure evolution and calcium distribution in sol-
gel derived bioactive glass. Journal of Materials Chem-
istry 19:1276–7282
21. Lowell S, Shields JE, Thomas MA, Thommes M (2004)
Characterization of porous solids and powders: Surface
area, pore size and density. Springer
22. Sing KSW (1985) Reporting physisorption data for
gas/solid systems with special reference to the determi-
nation of surface area and porosity. Pure and Applied
Chemistry 57:603–619
23. Sepulveda P, Jones JR, Hench LL (2002) In vitro dis-
solution of melt-derived 45S5 and sol-gel derived 58S
bioactive glasses. Journal of Biomedical Materials Re-
search 61:301–311
24. Arcos D, Vallet-Regı´ M (2010) Sol-gel silica-based bio-
materials and bone tissue regeneration. Acta Biomateri-
alia 6:2876–2888
25. Jones JR (2013) Review of bioactive glass: From Hench
to hybrids. Acta Biomaterialia 9:4457–4486
26. Ra´mila A, Vallet-Regı´ M (2001) Static and dynamic in
vitro study of a sol-gel glass bioactivity. Biomaterials
22:2301–2306
27. Oliveira JM, Correia RN, Fernandes M (2002) Effects
of Si speciation on the in vitro bioactivity of glasses.
Biomaterials 23:371379
28. Li P, Ohtsuki C, Kokubo T, Soga N, de Groot K (1994)
The role of hydradted silica, titania and alumina in in-
ducing apatite on implants. Journal of Biomedical Ma-
terials Research 28:7–15
29. Raynaud S, Champion E, Bernache-Assollant D,
Thomas P (2002) Calcium phosphate apatites with vari-
able Ca/P atomic ratio I. Synthesis, characterisation and
thermal stability of powders. Biomaterials 23:10651072
30. Stocha A, bskia WJ, Brozeka A, Stochb J, Szaranieca
J, Trybalskaa B, Kmita G (2000) FTIR absorption-
reflection study of biomimetic growth of phosphates
on titanium implants. Journal of Molecular Structure
10 Anthony L. B. Mac¸on et al.
555:375382
31. Mu`ller L, Mu`ller FA (2006) Preparation of SBF with
different HCO−3 content and its influence on the com-
position of biomimetic apatites. Acta Biomaterialia
2:181–189
32. Elliot JC, editor (1994) Structure and chemistry of the
apatites and other calcium orthophosphates. Amster-
dam: Elsevier Science
33. Gisbon IR, Rehman I, Best SM, Bonfield W (2000)
Characterization of the transformation from calcium-
deficient apatite to β -tricalcium phosphate. Journal of
Materials Science: Materials in Medicine 12:799–804
34. Martı´nez A, Izquierdo-Barba I, Vallet-Regı´ M (2000)
Bioactivity of a CaO-SiO2 Binary Glasses System.
Chemistry of Materials 12:3080–3088
35. Jalota S, Bhaduri SB, Tas AC (2004) Effect of carbonate
content and buffer type on calcium phosphate formation
in SBF solutions. Journal of Materials Science: Materi-
als in Medicine 17:697–707
36. Watts SJ, Hill RG, O’Donnell MD, Law RV (2010)
Influence of magnesia on the structure and properties
of bioactive glasses. Journal of Non-Crystalline Solids
356:517–524
